Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2021

Nov 2, 2021

30198_dirs_2021-11-02_df285e16-fdf5-4ff6-befb-f2a25349afa3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2021-10-29

Reporting Person: AUGUSTINOS NICHOLAS (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-10-29 Common Stock S 2500 $600.0347 Disposed 918 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 7592 Indirect

Footnotes

F1: On March 4, 2021, Mr. Augustinos adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Augustinos. The sale of shares set forth above were pursuant to the 10b5-1 Plan.

F2: This transaction was executed in multiple trades at prices ranging from $600.00 to $600.295. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3: Included in this number are 918 restricted stock units which were granted on May 21, 2021 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2022 Annual Meeting.